Accepted Articles
Back to the articles list |
Back to browse issues page
Abdollah Golnezhad1 
, Anahita Torkaman-Boutorabi2 , Emran Mohammad Razaghi3 , Mohammad Reza Zarrindast4 , Mohammad Reza Mahdavi5 , Nasim Vousooghi * 6
, Anahita Torkaman-Boutorabi2 , Emran Mohammad Razaghi3 , Mohammad Reza Zarrindast4 , Mohammad Reza Mahdavi5 , Nasim Vousooghi * 6
1- Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
2- Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.; Research Center for Cognitive and Behavioral Sciences, Tehran University of Medical Sciences, Tehran, Iran.
3- Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran.
4- Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.; Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran.
5- Thalassemia Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran.
6- Research Center for Cognitive and Behavioral Sciences, Tehran University of Medical Sciences, Tehran, Iran.; Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran.; Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
2- Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.; Research Center for Cognitive and Behavioral Sciences, Tehran University of Medical Sciences, Tehran, Iran.
3- Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran.
4- Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.; Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran.
5- Thalassemia Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran.
6- Research Center for Cognitive and Behavioral Sciences, Tehran University of Medical Sciences, Tehran, Iran.; Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran.; Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Abstract:
Background: Treatment of opioid use disorders via safe and effective approaches has been investigated for years, from the past to the present. Methadone maintenance treatment (MMT) has been considered an effective therapy for opioid addiction. It has been observed that patients with genetic polymorphisms often show variability in the optimal drug dose requirement and treatment schedule. This study aimed to investigate the relationship between single nucleotide polymorphisms (SNPs) in the ATP-binding cassette subfamily B member-1 (ABCB1), the mu-opioid receptor (OPRM1), and cytochrome P450 (CYP) genes and methadone dose in patients undergoing MMT in Mazandaran province in Iran.
Methods: In a cross-sectional study, 216 male MMT patients (20 to 45 years old) who were involved in the treatment program for at least three months were randomly recruited from six MMT clinics in Mazandaran province between 2018 and 2020. Blood samples were taken, DNA was extracted, and SNPs of CYP2B6 (G516T, A785G), CYP2C19 (-3402C>T), CYP3A4 (-392A>G), OPRM1 )A118G), and ABCB1 (C3435T, G2677T, G2677A, and C1236T) genes were evaluated using polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP).
Results: Our results showed no significant relationship between all the studied genotypes and methadone dose requirements.
Conclusion: The present study, for the first time in the Mazandaran population, reported no significant correlations between methadone dose requirement and different SNPs in the ABCB1, OPRM1, and CYP genes in MMT patients, which is consistent with other studies conducted on the Iranian population.
Methods: In a cross-sectional study, 216 male MMT patients (20 to 45 years old) who were involved in the treatment program for at least three months were randomly recruited from six MMT clinics in Mazandaran province between 2018 and 2020. Blood samples were taken, DNA was extracted, and SNPs of CYP2B6 (G516T, A785G), CYP2C19 (-3402C>T), CYP3A4 (-392A>G), OPRM1 )A118G), and ABCB1 (C3435T, G2677T, G2677A, and C1236T) genes were evaluated using polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP).
Results: Our results showed no significant relationship between all the studied genotypes and methadone dose requirements.
Conclusion: The present study, for the first time in the Mazandaran population, reported no significant correlations between methadone dose requirement and different SNPs in the ABCB1, OPRM1, and CYP genes in MMT patients, which is consistent with other studies conducted on the Iranian population.
Type of Study: Original |
Subject:
Clinical Neuroscience
Received: 2022/10/27 | Accepted: 2023/02/14
Received: 2022/10/27 | Accepted: 2023/02/14
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
